These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 24408121

  • 1. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 2. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, Hirakata H, Kitazono T, Tsuruya K.
    Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
    [Abstract] [Full Text] [Related]

  • 3. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF, VA NEPHRON-D Study Group.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2159-69. PubMed ID: 26482258
    [Abstract] [Full Text] [Related]

  • 4. Predictors of Progression in IgA Nephropathy in Childhood.
    Mizerska-Wasiak M, Małdyk J, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Bieniaś B, Zajączkowska M, Miklaszewska M, Pietrzyk J, Demkow U, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Adv Exp Med Biol; 2017 Dec 07; 955():65-73. PubMed ID: 27718216
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T, Najafi I, Salimi BH, Broomand B.
    Ren Fail; 2011 Dec 07; 33(6):572-7. PubMed ID: 21663387
    [Abstract] [Full Text] [Related]

  • 6. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T, Nakayama K, Ochi A, Amemiya N, Tsuruta Y, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.
    Clin Exp Nephrol; 2012 Apr 07; 16(2):231-7. PubMed ID: 22038185
    [Abstract] [Full Text] [Related]

  • 7. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb 07; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 8. Predictors for progression in immunoglobulin A nephropathy with significant proteinuria.
    Hwang HS, Kim BS, Shin YS, Yoon HE, Song JC, Choi BS, Park CW, Yang CW, Kim YS, Bang BK.
    Nephrology (Carlton); 2010 Mar 07; 15(2):236-41. PubMed ID: 20470285
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
    Omae K, Ogawa T, Nitta K.
    Heart Vessels; 2010 May 07; 25(3):203-8. PubMed ID: 20512447
    [Abstract] [Full Text] [Related]

  • 10. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J, PRONEDI Study Group.
    Clin J Am Soc Nephrol; 2013 Nov 07; 8(11):1870-6. PubMed ID: 24135218
    [Abstract] [Full Text] [Related]

  • 11. Treatment of IgA nephropathy.
    Pozzi C.
    J Nephrol; 2016 Feb 07; 29(1):21-5. PubMed ID: 26577268
    [Abstract] [Full Text] [Related]

  • 12. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 13. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec 06; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

  • 14. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.
    Clin J Am Soc Nephrol; 2009 Feb 06; 4(2):361-8. PubMed ID: 19118120
    [Abstract] [Full Text] [Related]

  • 15. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH, Lee JE, Park JH, Lim S, Jang HR, Kwon GY, Huh W, Jung SH, Kim YG, Oh HY, Kim DJ.
    Ann Med; 2016 Feb 06; 48(3):171-81. PubMed ID: 27031662
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Outcomes in IgA Nephropathy.
    Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J.
    Clin J Am Soc Nephrol; 2023 Jun 01; 18(6):727-738. PubMed ID: 37055195
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 01; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 18. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.
    Am J Kidney Dis; 2000 Jun 01; 35(6):1155-65. PubMed ID: 10845831
    [Abstract] [Full Text] [Related]

  • 19. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    BMC Nephrol; 2017 Mar 14; 18(1):89. PubMed ID: 28292274
    [Abstract] [Full Text] [Related]

  • 20. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group.
    J Am Soc Nephrol; 2015 Sep 14; 26(9):2248-58. PubMed ID: 25677392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.